10 December 2024
Nadezda Koytova
Over the past few weeks, the TCP team visited multiple clinical trial sites to evaluate and select locations for future capacity development
Over the past two to three weeks, the TCP team has conducted multiple visits to clinical trial sites across the designated countries as part of the Track A efforts under the ARC-WA project. These visits are a critical step in assessing the current infrastructure, capabilities, and readiness of the sites. The primary objective is to evaluate and identify a selection of clinical trial sites that will undergo further capacity development, ensuring they are well-prepared to support future large-scale vaccine trials.
This initiative is specifically aimed at strengthening sites in Lassa fever endemic areas to facilitate their participation in a potential Phase 3 Lassa fever vaccine trial. By focusing on this rigorous site selection and preparation process, we are laying the groundwork for high-quality research that could contribute significantly to the fight against Lassa fever and enhance regional capacity for conducting advanced clinical trials.